Skip to main content

John Robert Perfect

James B. Duke Distinguished Professor of Medicine
Medicine, Infectious Diseases
Duke Box 102359, Durham, NC 27710
Hanes House Rm 163, Trent Drive, Durham, NC 27710

Selected Grants


Tri-Institutional Molecular Mycology and Pathogenesis Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029

Stimulating Access to Research in Residency (StARR) - NIAID

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2018 - 2029

The Role of Inositol in Cryptococcus Biology and Pathogenesis

ResearchPrincipal Investigator · Awarded by Rutgers, The State University of New Jersey · 2024 - 2029

Targeting Hsp90 in cryptococcal fungal pathogenesis

ResearchPrincipal Investigator · Awarded by University of Toronto · 2024 - 2027

Interdisciplinary Research Training Program in AIDS

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2025

Genetic and Genomics Training Grant

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2020 - 2025

Population Structure and Clinical Impact of Multi-strain and Mixed-species Cryptococcal Infections

ResearchCo-Principal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2023 - 2025

Advancing genomic, transcriptomic and functional approaches to combat globally important and emerging pathogens (U19)

ResearchPrincipal Investigator · Awarded by Broad Institute · 2019 - 2025

Host directed medicine in invasive fungal infection - HDM-FUN

Clinical TrialPrincipal Investigator · Awarded by European Union · 2020 - 2024

Transplant Infectious Diseases Interdisciplinary Research Training Grant (TIDIRTG)

Inst. Training Prgm or CMEAdvisor · Awarded by National Institutes of Health · 2018 - 2024

Duke CTSA (TL1) Year 5

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024

Biosynthesis of antifungal nucleoside antibiotics

ResearchCollaborating Investigator · Awarded by National Institutes of Health · 2015 - 2024

Evolution of Cryptococcus neoformans Strains from Patients with HIV/AIDS

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2024

AM-2-19 Efficacy Testing in a Mouse Model of Cryptococcosis

ResearchPrincipal Investigator · Awarded by Sfunga Therapeutics · 2022 - 2023

Development of a new class of antifungals effective against Cryptococcus

ResearchPrincipal Investigator · Awarded by Linnaeus Bioscience Inc. · 2019 - 2023

Phase II, study to evaluate the safety of APX001 with Invasive mold infections caused by Aspergillus or rare mold

Clinical TrialPrincipal Investigator · Awarded by Amplyx Pharmaceuticals, Inc. · 2020 - 2023

Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

ResearchCo Investigator · Awarded by Minnetronix, Inc · 2018 - 2022

Mentoring Patient Oriented Research in Antibiotic-Resistant Bacteria

ResearchAdvisor · Awarded by National Institutes of Health · 2011 - 2022

The Role of Host Inositol in Cryptococcus Biology and Pathogenesis

ResearchPrincipal Investigator · Awarded by Rutgers, The State University of New Jersey · 2016 - 2021

Transdisciplinary Program to Identify Novel Antifungal Targets and Inhibitors

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2021

Analysis of APX2039 in Rabbit Plasma, CSF and Brain Tissue Samples

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2020

Genetics Training Grant

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1979 - 2020

APX001-201 SURGE

Clinical TrialPrincipal Investigator · Awarded by Amplyx Pharmaceuticals, Inc. · 2018 - 2020

Pathobiology of C. neoformans in the Central Nervous System

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2020

Study Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis Caused by Cryptococccal gattii

ResearchPrincipal Investigator · Awarded by Astellas Pharma Inc. · 2017 - 2019

APX001 with Fluconazole in a Murine Model of Cryptococcosis

ResearchPrincipal Investigator · Awarded by Amplyx Pharmaceuticals, Inc. · 2016 - 2019

Validation of a Novel Therapeutic Approach for Cryptococcal Meningitis

ResearchCo Investigator · Awarded by Minnetronix, Inc · 2017 - 2018

Mouse Study to Evaluate Efficacy of VL-2397 Against Cryptococcal Meningitis

ResearchPrincipal Investigator · Awarded by Vical, Inc. · 2018 - 2018

T2 Bacteria Panel Pivotal Study

Clinical TrialPrincipal Investigator · Awarded by T2 Biosystems, Inc · 2016 - 2017

Cryptococcus Neoformans

ResearchCo Investigator · Awarded by Minnetronix, Inc · 2015 - 2017

Cryptococcus Infection Network Cohort study for non-HIV Patients: The CINCH Study

ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2014 - 2017

Cryptococcus Neoformans

ResearchCo Investigator · Awarded by Minnetronix, Inc · 2015 - 2016

Institutional Training Grant in Pediatric Infectious Disease

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2011 - 2016

A Computer Modeling Approach to Create an Antifungal to Improve the Treatment of Cryptococcal Infections

ResearchPrincipal Investigator · Awarded by Amplyx Pharmaceuticals, Inc. · 2015 - 2016

Evolution of Cryptococcus neoformans strains from patients with HIV/AIDS

ResearchCo Investigator · Awarded by National Institutes of Health · 2011 - 2016

VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053

Clinical TrialSenior Investigator · Awarded by National Institutes of Health · 2015 - 2016

Molecular Umbrella-Amphotericin B Conjugates

ResearchPrincipal Investigator · Awarded by Lehigh University · 2012 - 2016

Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development

Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2014 - 2015

Novel Antifungal Therapeutic Approaches

ResearchCo Investigator · Awarded by National Institutes of Health · 2001 - 2014

Ras Signaling in C. neoformans virulence and development

ResearchInvestigator · Awarded by National Institutes of Health · 2008 - 2014

Pulmonary Surfactant and Lung Homeostasis

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 2014

Mid-Career Investigator Award: Preventing and Diagnosing Fungal Disease in Transplantation

ResearchCollaborator · Awarded by National Institutes of Health · 2007 - 2013

The effects of Nlrp12 and IL-1b in inflammatory disorders

ResearchCollaborator · Awarded by National Institutes of Health · 2010 - 2012

Microfluidic PCR Platform to Detect Microbial DNA

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2005 - 2010

Calcineurin and Aspergillus fumigatus Pathogenesis

ResearchMentor · Awarded by National Institutes of Health · 2004 - 2010

Role of Calcineurin in Fungal Virulence

ResearchCo Investigator · Awarded by National Institutes of Health · 2004 - 2010

Early Diagnosis of Neonatal Candidiasis

ResearchCo-Mentor · Awarded by National Institutes of Health · 2005 - 2009

Genetic Determinants of A. Fumigatus Susceptibility

ResearchMentor · Awarded by National Institutes of Health · 2005 - 2009

Host-Response relationships in patients with candidemia

ResearchMentor · Awarded by National Institutes of Health · 2002 - 2008

Genetic molecular biology of virulence in C. neoformans

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 2008

Prevention & dx of fungal infxns in transplantation

ResearchMentor · Awarded by National Institutes of Health · 2002 - 2007

Mentored Clinical Research Scholar Program

ResearchMentor · Awarded by National Institutes of Health · 2002 - 2006

Cryptococcus Neoformans - A Model for Pathogenic Fungi

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2005

Genetic Molecular Biology of Virulence in C. Neoformans

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2004

same

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2004

Cryptococcus neoformans: A model for pathogenic fungi

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2004

Same

ResearchCo Investigator · Awarded by National Institutes of Health · 1998 - 2003

Ras signaling in C. neoformans virulence and development

ResearchCo Investigator · Awarded by National Institutes of Health · 2002 - 2003

Same

ResearchCo Investigator · Awarded by National Institutes of Health · 1997 - 2001

Genetic Molecular Biology Of Virulence In C Neoformans

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 2000

Duke University Adult Aids Clinical Trails Unit

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1996 - 1999

Adult Aids Clinical Trials Unit

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1996 - 1999

Novel Antifungal Drug Targets In Cryptococcus Neoformans

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1997 - 1999

Immunosuppressant Targets In Cryptococcus Neoformans

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1997 - 1999

Genetic & Molecular Biology Of Virulence In C. Neoformans

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1999

Genetic & Molecular Biology Of Virulence In C Neoformans

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1999

Genetic And Molecular Biology Of Virulence In C Neoformans

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1994

External Relationships


  • Astellas Pharma Inc.
  • F2G Pharmaceutical Company
  • Merck
  • Pfizer Inc.
  • Scynexis
  • Up to Date Inc

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.